

MY ECZEMA
ONCE DICTATED
WHO I WAS
NOW
I DEFINE
ME

CAMRIE

A REAL ADBRY PATIENT.
Individual results may vary.

Don't let moderate-to-severe eczema control your narrative—discover clearer skin and reduced itch with Adbry®.



INDICATION AND IMPORTANT SAFETY INFORMATION

What is ADBRY?

- ADBRY® (tralokinumab-ldrm) injection is a prescription medicine used to treat people 12 years of age and older with moderate-to-severe atopic dermatitis (eczema) that is not well controlled with prescription therapies used on the skin (topical), or who cannot use topical therapies. ADBRY can be used with or without topical corticosteroids.
- It is not known if ADBRY is safe and effective in children under 12 years of age.

Do not use ADBRY if you are allergic to tralokinumab or to any of its ingredients.

Please see Important Safety Information throughout this brochure and accompanying full Prescribing Information, including Patient Information and Instructions for Use.


Adbry[®]
(tralokinumab-ldrm)
Injection 150 mg • 300 mg



Now that my
eczema isn't all
I'm fixated on, I
can get back to

FOCUSING ON ME.

CAMRIE

A REAL ADBRY PATIENT.
Individual results may vary.

About atopic dermatitis (eczema)

Chronic inflammation beneath the skin

Atopic dermatitis is a type of eczema. In fact, it's the most common type, affecting more than 16 million adults in the United States.

Eczema is a chronic skin disease that's **caused by an overactive immune response**. When the immune response is triggered, it causes inflammation, and your skin can become itchy, red, and dry.

With eczema, the overactive immune response causes inflammation. So even when symptoms aren't present on your skin, **inflammation can still be happening under your skin**.

Unpredictable & frustrating

Moderate-to-severe eczema can be exhausting and often unpredictable—appearing at different times and on different parts of the body.

Eczema most commonly appears on the neck, hands, arms, back of the knees, and inside of the elbows.

IMPORTANT SAFETY INFORMATION (cont'd)

What should I discuss with my healthcare provider before starting ADBRY?

Tell your healthcare provider about all your medical conditions, including if you:

- have eye problems.
- have a parasitic (helminth) infection.

Please see Important Safety Information throughout this brochure and accompanying full Prescribing Information, including Patient Information and Instructions for Use.



Adbry[®]
(tralokinumab-ldrm)
Injection 150 mg • 300 mg

IL-13 triggers inflammation in your skin

The exact cause of eczema is unknown, but we do know it can involve:

- **Weakened barrier** of skin
- **Overactive immune response** that includes the creation of IL-13 (interleukin-13, a protein in the body)
- **Inflamed skin** resulting from signals from IL-13 activity




Studies have linked increased levels of IL-13 to the presence and severity of eczema.

The itch-scratch cycle

When the skin has too much IL-13, it leads to **inflammation** and unbearable **itching**.

This leads to **scratching** of the skin, which weakens and damages the skin barrier, allowing irritants to pass into the skin.


The immune system detects these irritants, so it responds by sending **more IL-13** to the area. And the cycle continues.



For illustrative purposes.

Adbry® works by helping to target and neutralize IL-13. When IL-13 is neutralized, it is unable to send signals that lead to eczema-related inflammation.

Adbry targets IL-13 to help calm eczema inflammation



IMPORTANT SAFETY INFORMATION (cont'd)

What should I discuss with my healthcare provider before starting ADBRY? (cont'd)

- are scheduled to receive any vaccinations. You should not receive a "live vaccine" if you are treated with ADBRY.
- are pregnant or plan to become pregnant. It is not known whether ADBRY will harm your unborn baby. There is a pregnancy exposure registry for women who use ADBRY during pregnancy. The purpose of this registry is to collect information about the health of you and your baby. You or your healthcare provider can get information and enroll you in this registry by calling 1-877-311-8972 or visiting <https://mothertobaby.org/ongoing-study/adbry-tralokinumab/>.

Please see Important Safety Information throughout this brochure and accompanying full Prescribing Information, including Patient Information and Instructions for Use.


Adbry®
(tralokinumab-ldrm)
Injection 150 mg • 300 mg

DEFINE THE **FUTURE** OF YOUR **SKIN**

JULIE

A REAL ADBRY PATIENT.
Individual results may vary.



Adbry[®] zeroes in on one of the main causes of eczema

Specifically targeted biologic



Adbry is not a cream, an ointment, or a pill. And it's not a topical corticosteroid. It's a biologic treatment that helps **calm the inflammation** that leads to the symptoms of eczema.



Adbry is the **first biologic injection that specifically targets IL-13**, one of the proteins in the immune system that contributes to skin inflammation in eczema.

A biologic is a type of medicine that is made from living organisms or components of living organisms. Adbry is an **antibody** and works with your immune system to **neutralize IL-13, helping prevent inflammation in your skin.**

IMPORTANT SAFETY INFORMATION (cont'd)

What should I discuss with my healthcare provider before starting ADBRY? (cont'd)

- are breastfeeding or plan to breastfeed. It is not known whether ADBRY passes into your breast milk and if it can harm your baby.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

Please see Important Safety Information throughout this brochure and accompanying full Prescribing Information, including Patient Information and Instructions for Use.


Adbry[®]
(tralokinumab-ldrm)
Injection 150 mg • 300 mg

When living with
moderate-to-severe eczema

Take control with Adbry®

It can be frustrating when your eczema is still not under control. Adbry **works inside the body** to help **get clearer skin and control the unbearable itch** for the long term. Adbry was used in 2 clinical trials for up to 1 year, and 1 trial for up to 8 months. Talk to your healthcare provider to see if Adbry is right for you.

How was Adbry studied in clinical trials?

Adbry was studied in 3 separate clinical trials of almost **2,000 adults** aged 18 and older with moderate-to-severe atopic dermatitis (eczema). Adults in the trials injected 2 prefilled syringes every other week.

TRIAL 1 601 adult patients used Adbry; 197 used placebo



TRIAL 2 577 adult patients used Adbry; 193 used placebo



TRIAL 3 243 adult patients used Adbry + topical corticosteroids; 123 used placebo + topical corticosteroids

IMPORTANT SAFETY INFORMATION (cont'd)

How should I use ADBRY?

- See the detailed “Instructions for Use” that comes with ADBRY for information on how to prepare and inject ADBRY and how to properly store and throw away (dispose of) used ADBRY prefilled syringes and autoinjectors.
- Use ADBRY exactly as prescribed by your healthcare provider.
- Your healthcare provider will tell you how much ADBRY to inject and when to inject it.
- ADBRY comes as a single-dose prefilled syringe with needle guard or as an autoinjector.
- ADBRY is given as an injection under the skin (subcutaneous injection).



The Adbry® clinical trials
mainly focused on:

The percentage of
adults who saw **clear
or almost clear skin**

The percentage of
adults **who had a
reduction in itch**

KALVIN

A REAL ADBRY PATIENT.
Individual results may vary.

What side effects were seen in clinical trials?

Adbry can cause serious side effects including:

Allergic reactions (hypersensitivity), including a severe reaction known as anaphylaxis. Stop using Adbry and tell your healthcare provider or get emergency help right away if you get any of the following symptoms: breathing problems; itching; skin rash; swelling of the face, mouth, and tongue; fainting, dizziness, feeling lightheaded (low blood pressure); or hives.

Eye problems. Tell your healthcare provider if you have any new or worsening eye problems, including eye pain or changes in vision. **The most common side effects of Adbry include:** upper respiratory tract infections; eye and eyelid inflammation, including redness, swelling, and itching; injection site reactions; and high count of a certain white blood cell (eosinophilia). These are not all of the possible side effects of Adbry.

With Adbry, there are no initial lab tests or routine lab monitoring required.

Please see Important Safety Information throughout this brochure and accompanying full Prescribing Information, including Patient Information and Instructions for Use.


Adbry®
(tralokinumab-ldrm)
Injection 150 mg • 300 mg

Clearer skin and less itch

TRIAL 3: Adbry® + topical corticosteroids vs placebo + topical corticosteroids

243 adults used Adbry every other week + topical corticosteroids as needed; 123 adults used placebo every other week + topical corticosteroids as needed.

CLEAR OR ALMOST CLEAR SKIN

4 MONTHS

ALMOST

40%

of adults vs 27% using placebo

8 MONTHS

89%

maintained clear or almost clear skin



Additional results

After 4 months, almost 50% of adults experienced **significantly less itch** (vs 35% of adults using placebo)

IMPORTANT SAFETY INFORMATION (cont'd)

How should I use ADBRY? (cont'd)

- If your healthcare provider decides that you or a caregiver can give the injections of ADBRY, you or your caregiver should receive training on the right way to prepare and inject ADBRY. **Do not** try to inject ADBRY until you have been shown the right way by your healthcare provider. In children 12 years of age and older, it is recommended that ADBRY be given by or under supervision of an adult.

ALSO PROVEN IN CHILDREN AGES

12-17

Adbry® showed similar results* in children ages 12-17 years and adults with moderate-to-severe severe eczema.

*Based on data gathered from multiple studies (2,126 patients combined).

JULIE

A REAL ADBRY PATIENT.
Individual results may vary.



75% OR BETTER IMPROVEMENT IN SKIN

4 MONTHS

ALMOST

56%

of adults vs 37% using placebo

8 MONTHS

92%

maintained 75% or better improvement in skin

Across Trials 1, 2, and 3, more adults using Adbry saw a **90% or better improvement** in their skin compared to those using placebo.

Please see Important Safety Information throughout this brochure and accompanying full Prescribing Information, including Patient Information and Instructions for Use.


Adbry®
(tralokinumab-ldrm)
Injection 150 mg • 300 mg

Clearer skin and less itch

TRIAL 1: Adbry® alone vs placebo

601 adults used Adbry every other week; 197 used placebo every other week.

At 4 months of Adbry alone

- 16% of adults saw **clear or almost clear skin** (vs 7% of adults using placebo)
- 25% of adults saw a **75% or better improvement in skin** (vs 13% of adults using placebo)



20% of adults experienced less itch (vs 10% of adults using placebo).

TRIAL 1

1 YEAR RESULTS

51%

of adults maintained clear or almost clear skin

ALMOST

60%

of adults maintained a 75% or better improvement in skin

IMPORTANT SAFETY INFORMATION (cont'd)

How should I use ADBRY? (cont'd)

- If you miss a dose, inject the missed dose as soon as possible, then continue with your next dose at your regular scheduled time.
- If you inject too much ADBRY than prescribed, call your healthcare provider or call Poison Help line at 1-800-222-1222 or go to the nearest hospital emergency room right away.



At the end of Week 1, adults taking Adbry® achieved a 9% improvement* in itch versus 3% for those who did not receive Adbry.

*Based on data gathered from Trials 1 and 2 (1,556 patients combined).

TRIAL 2: Adbry alone vs placebo

577 adults used Adbry every other week; 193 used placebo every other week.

At 4 months of Adbry alone

- 21% of adults saw **clear or almost clear skin** (vs 9% of adults using placebo)
- 33% of adults saw a **75% or better improvement in skin** (vs 10% of adults using placebo)



25% of adults experienced less itch (vs 9% of adults using placebo).

TRIAL 2

1 YEAR RESULTS

60%

of adults maintained clear or almost clear skin

ALMOST

57%

of adults maintained a 75% or better improvement in skin

- Your healthcare provider may prescribe other medicines to use with ADBRY. Use the other prescribed medicines exactly as your healthcare provider tells you to.

Please see Important Safety Information throughout this brochure and accompanying full Prescribing Information, including Patient Information and Instructions for Use.


Adbry®
(tralokinumab-ldrm)
Injection 150 mg • 300 mg

JULIE

A REAL ADBRY PATIENT.
Individual results may vary.



KALVIN


A REAL ADBRY PATIENT.
Individual results may vary.



On your way to clearer skin and less itch

When you begin taking Adbry®, you will get a one-time starter dose that helps build up the medicine in your body.

Your doctor, healthcare team, or caregiver will explain how to inject yourself. You can also consult step-by-step how-to videos at [Adbry.com](https://www.adbry.com).



Learn to self-inject
Scan the code to
watch the Adbry
self-injection
training videos

IMPORTANT SAFETY INFORMATION (cont'd)

What are the possible side effects of ADBRY? (cont'd)

ADBRY can cause serious side effects including:

- **Allergic reactions (hypersensitivity), including a severe reaction known as anaphylaxis.** Stop using ADBRY and tell your healthcare provider or get emergency help right away if you get any of the following symptoms:
 - breathing problems
 - itching
 - skin rash
 - swelling of the face, mouth, and tongue
 - fainting, dizziness, feeling lightheaded (low blood pressure)
 - hives

Please see Important Safety Information throughout this brochure and accompanying full Prescribing Information, including Patient Information and Instructions for Use.


Adbry[®]
(tralokinumab-ldrm)
Injection 150 mg • 300 mg

You've got options with Adbry®

FOR ADULTS

Device options



Autoinjector

OR



Prefilled syringe

Dosing


One-time starter dose:

You'll start with **two** 300-mg autoinjectors **OR** four 150-mg prefilled syringes

Maintenance dose:


Then, every other week you'll inject one 300-mg autoinjector **OR** two 150-mg prefilled syringes

Dosing options after 16 weeks



Continue every other week

OR



Reduce to once-monthly*

After 16 weeks, your healthcare provider will determine if you can switch to taking Adbry once a month

*Healthcare provider may consider this dosing option for adults <220 lbs who have achieved clear or mostly clear skin after taking Adbry for at least 16 weeks.

DOSING FOR PEDIATRIC PATIENTS (12-17 years)

One-time starter dose:

two 150-mg prefilled syringes (300 mg)

Maintenance dose:

one 150-mg prefilled syringe every other week



Prefilled syringe

IMPORTANT SAFETY INFORMATION (cont'd)

What are the possible side effects of ADBRY? (cont'd)

ADBRY can cause serious side effects including:

- **Eye problems.** Tell your healthcare provider if you have any new or worsening eye problems, including eye pain or changes in vision.

The most common side effects of ADBRY include:

- Upper respiratory tract infections
- Eye and eyelid inflammation, including redness, swelling, and itching



Not actual size.

It's okay if you have questions about how to inject.

Just review your **Instructions for Use brochure** ("A step-by-step guide to injecting at home") or reach out to your healthcare provider.

CAMRIE

A REAL ADBRY PATIENT.
Individual results may vary.

Please see Important Safety Information throughout this brochure and accompanying full Prescribing Information, including Patient Information and Instructions for Use.


Adbry[®]
(tralokinumab-ldrm)
Injection 150 mg • 300 mg

PATIENT SUPPORT THAT'S FOCUSED ON **ME**



JULIE

A REAL ADBRY PATIENT.
Individual results may vary.

Support when you need it

When you're taking Adbry®, you're not alone.

If you have questions, need support, or would like resources during your treatment, you can turn to the Adbry® Advocate™ Program.



Here to help
Scan to find out more
about the Adbry®
Advocate™ Program.



KALVIN

A REAL ADBRY PATIENT.
Individual results may vary.

IMPORTANT SAFETY INFORMATION (*cont'd*)

The most common side effects of ADBRY include (*cont'd*):

- Injection site reactions
- High count of a certain white blood cell (eosinophilia)

Please see Important Safety Information throughout this brochure and accompanying full Prescribing Information, including Patient Information and Instructions for Use.




Adbry[®]
(tralokinumab-ldrm)
Injection 150 mg • 300 mg

FOCUS ON YOU

NOT YOUR ECZEMA, with the long-term control of Adbry®

KALVIN

A REAL ADBRY PATIENT.
Individual results may vary.



Share your voice

Already using Adbry? Adbry® Voices™ is an ambassador program where you and others in the Adbry community can help those considering treatment. By sharing your story, you can offer insight from your own personal journey and help others to take control of their eczema.

Visit [Adbry.com/voices](https://adbry.com/voices) to sign up.

IMPORTANT SAFETY INFORMATION (cont'd)

The most common side effects of ADBRY include (cont'd):

These are not all the possible side effects of ADBRY. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Please see Important Safety Information throughout this brochure and accompanying full Prescribing Information, including Patient Information and Instructions for Use.



The LEO Pharma logo and Adbry® are registered trademarks of LEO Pharma A/S. Advocate™ and Voices™ are trademarks of LEO Pharma A/S. © 2024 LEO Pharma Inc. All rights reserved. MAT-70123 August 2024

Adbry®
(tralokinumab-ldrm)
Injection 150 mg • 300 mg

The logo features the word 'Adbry' in a blue serif font with a registered trademark symbol, followed by '(tralokinumab-ldrm)' in a blue sans-serif font. Below this is the text 'Injection 150 mg • 300 mg'. To the right of the text is a stylized graphic of three overlapping human figures in blue, purple, and pink, with a blue wave-like line above them.